Perth-based biotechnology company pSivida Ltd will raise $3.7 million through a placement to Australian and European investors, to fund development of its macular edema treatment.

 

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

(first time users)
FREE: 8 articles per month + twice daily business email alerts